Scleroderma News

It’s not too often one sees Feb. 29 on the calendar, which makes it a perfect time for Rare Disease Day, dedicated to recognizing conditions that, in the words of the European Commission on Public Health, require “special combined efforts.”

Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.

SCOTTSDALE, Ariz. — Chimeric antigen receptor T-cell therapy had “unprecedented” and “astonishing” results in lupus, but whether it will truly revolutionize rheumatology care remains to be seen, according to a speaker.

Hispanic patients with systemic sclerosis are more likely to have concurrent systemic lupus erythematosus and U1-RNP positivity, and face greater mortality rates vs. non-Hispanic white patients, according to data.

Chimeric antigen receptor T-cell therapy produced persistent, drug-free remission in patients with one of three different B-cell autoimmune diseases, researchers reported at ASH Annual Meeting and Exhibition.

As much as 43% of patients with systemic sclerosis demonstrate evidence of myopathy, while those with proximal weakness and higher creatine kinase exhibit worse function and survival, according to data.

Celltrion USA has submitted a Biologics License Application to the FDA for its tocilizumab biosimilar candidate CT-P47, according to a press release.

Patients with higher levels of gamma-glutamyl transferase, and particularly men, demonstrate a significantly higher risk for systemic sclerosis, according to data published in Nature Scientific Reports.

Come the new year, a “mini” pill could have a massive impact in rheumatology care.

SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.